The “Forcing Function” of JPM
Biopharma companies need to balance many critical priorities, especially those…
BIO and Boston: The Global Stage and HLYB
Attending a large conference, medical congress, or trade show can be both…
Season of Transitions
Three notable transitions worthy of reflection at this point in time.
Medical Affairs Is Stepping Into the Future
The energy was palpable at the 2025 Medical Affairs Professional Society (MAPS) Global Annual Meeting. Conversations were expansive, workshops…
The Power of Key Business Questions
In our biopharma world, we frequently hear the term “Key Business Questions (KBQs).” And while it’s often thrown around as a buzzword (or buzz…
Biopharma Annual Planning Success: Close Your Rings Year-Round
How do we think about biopharma annual planning differently? The analogy we will draw on is fitness trackers and apps—built for mindfulness and…
The Power of Target Product Profiles: Three Case Studies
In the biopharma industry, the Target Product Profile (TPP) is a critical tool for guiding the development and commercialization of new drugs.
Unlocking Success: The Power of Target Product Profiles
In the ever-evolving biopharma landscape, success hinges not just on innovation but also on a clear roadmap guiding clinical and commercial…
Governance: The Glue to a Successful Launch
At the core of every successful launch lies a meticulously crafted plan, a robust governance structure, and expert management of its execution.
Your Biopharma Data Needs a Strategy
In the not-so-distant past, physician prescribing data was essentially a commodity with limited breadth or depth for the purposes of drug development…
Juggling Geographic Commercialization Priorities
Commercializing a pharmaceutical asset in one country is hard enough. Doing it on a global scale, with multiple country differences, is exponentially…